Characterization of cell migration in response to benvitimod and its stabilized derivative INPS1001

Skin diseases such as psoriasis and eczema are common and cause discomfort in skin lesions. Psoriasis is a chronic disease with cycles of unknown triggers. Currently treatments for psoriasis are very limited. A special bacterium-produced compound called benvitimod has demonstrated effects on treating both psoriasis and eczema by suppressing inflammation and promoting cell migration. However, benvitimod is unstable for topical use. A chemically modified benvitimod derivative, INPS1001 , is stable for topical application and has demonstrated effects in treating eczema. This Mitac Accelerate program will seek the molecular fundamentals of such an effect by examining the cell migration rate difference between benvitimod and INPS1001 . The obtained information will help understand how INPS1001 exhibits its healing power and help to discover other suitable diseases that INPS1001 could treat.

Faculty Supervisor:

Bingyun Sun

Student:

Partner:

PL Laboratories Inc.

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

Simon Fraser University

Program: